Gloria Iacoboni

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 95 publications

Second Primary Malignant Neoplasms After T-Cell-Engaging Bispecific Antibody Therapy: A Systematic Review and Meta-Analysis.

Second Primary Malignant Neoplasms After T-Cell-Engaging Bispecific Antibody Therapy: A Systematic Review and Meta-Analysis.

Journal: JAMA oncology

Published: June 18, 2026

Real-world CAR-T practice patterns in patients with mantle cell lymphoma: an international survey on behalf of the EBMT lymphoma working party.

Real-world CAR-T practice patterns in patients with mantle cell lymphoma: an international survey on behalf of the EBMT lymphoma working party.

Journal: Bone marrow transplantation

Published: April 12, 2026

Timing is everything: the CAR T-cell clock is ticking.

Timing is everything: the CAR T-cell clock is ticking.

Journal: Blood

Published: March 19, 2026

Cellular therapy in mantle cell lymphoma: recommendations from the EBMT practice harmonisation and guidelines committee.

Cellular therapy in mantle cell lymphoma: recommendations from the EBMT practice harmonisation and guidelines committee.

Journal: Bone marrow transplantation

Published: March 08, 2026

Real-world resource utilization, toxicity management, and efficacy outcomes of CD20 × CD3 bispecific antibodies in B-cell lymphoma: A study from the GELTAMO network.

Real-world resource utilization, toxicity management, and efficacy outcomes of CD20 × CD3 bispecific antibodies in B-cell lymphoma: A study from the GELTAMO network.

Journal: HemaSphere

Published: December 11, 2025

Selecting the best treatment approach and optimizing sequencing strategies in large B-cell lymphoma.

Selecting the best treatment approach and optimizing sequencing strategies in large B-cell lymphoma.

Journal: Hematology. American Society of Hematology. Education Program

Published: December 05, 2025

Impact of fludarabine exposure on CAR T-cell outcomes in patients with large B-cell lymphoma.

Impact of fludarabine exposure on CAR T-cell outcomes in patients with large B-cell lymphoma.

Journal: Blood advances

Published: December 04, 2025

Impact of fludarabine exposure on CAR T-cell outcomes in patients with large B-cell lymphoma.

Impact of fludarabine exposure on CAR T-cell outcomes in patients with large B-cell lymphoma.

Journal: Blood advances

Published: December 04, 2025

Immunotherapy may be preferable to chemotherapy for patients with POD24 follicular lymphoma in the second-line setting.

Immunotherapy may be preferable to chemotherapy for patients with POD24 follicular lymphoma in the second-line setting.

Journal: British journal of haematology

Published: November 03, 2025

Towards Personalized Lymphodepletion: A Population Pharmacokinetic Fludarabine Model in Patients Receiving CAR T-Cell Therapy.

Towards Personalized Lymphodepletion: A Population Pharmacokinetic Fludarabine Model in Patients Receiving CAR T-Cell Therapy.

Journal: Pharmaceutics

Published: October 27, 2025

Impact of prior bendamustine exposure on bispecific antibody outcomes in relapsed/refractory follicular lymphoma.

Impact of prior bendamustine exposure on bispecific antibody outcomes in relapsed/refractory follicular lymphoma.

Journal: Blood advances

Published: September 25, 2025

Impact of Prior Bendamustine Exposure on Bispecific Antibody Outcomes in Relapsed/Refractory Follicular Lymphoma.

Impact of Prior Bendamustine Exposure on Bispecific Antibody Outcomes in Relapsed/Refractory Follicular Lymphoma.

Journal: Blood advances

Published: September 25, 2025

Showing 1-12 of 95

Last Updated: 09/26/2026